Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

AstraZeneca Signs Three Cancer Pacts

by Lisa M. Jarvis
January 13, 2014 | A version of this story appeared in Volume 92, Issue 2

AstraZeneca last week inked three deals to bolster its oncology pipeline. MedImmune, the biologics arm of AstraZeneca, has partnered with biotech firm Immunocore to develop therapeutics that send patients’ T cells out to combat cancer cells. For each cancer immunotherapy developed, Immunocore scores $20 million up front and up to $300 million in milestone payments. AstraZeneca also signed a deal with Horizon Discovery to identify and validate drug targets by exploiting the concept of synthetic lethality, in which mutations in two genes are required for cell death. Finally, AstraZeneca bought the rights to Probiodrug’s cyclin-dependent kinase 9 inhibitor, which blocks a target implicated in cancer and inflammatory diseases, and related compounds.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.